<p>Cencora（紐約證券交易所代碼：COR）在過去三個月內被 11 位分析師分析，揭示了從看漲到看跌的多樣化觀點。</p>
<p>下表概括了他們最近的評級，提供了過去 30 天情緒變化的快照，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師提供的 12 個月價格目標顯示出平均目標為 393.82 美元，最高預估為 440.00 美元，最低預估為 340.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的 351.70 美元的平均價格目標增加了 11.98%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769119275_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769119275_0.png"/></p>
<h2>分析師評級探討：深入概述</h2>
<p>通過審視最近的分析師行動，我們可以瞭解金融專家如何看待 Cencora。以下摘要概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>上調</td>
<td>買入</td>
<td>440.00 美元</td>
<td>330.00 美元</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>下調</td>
<td>中性</td>
<td>360.00 美元</td>
<td>380.00 美元</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>宣佈</td>
<td>超配</td>
<td>400.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>上調</td>
<td>超配</td>
<td>417.00 美元</td>
<td>344.00 美元</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>上調</td>
<td>超配</td>
<td>405.00 美元</td>
<td>354.00 美元</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>上調</td>
<td>買入</td>
<td>400.00 美元</td>
<td>350.00 美元</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上調</td>
<td>買入</td>
<td>415.00 美元</td>
<td>380.00 美元</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>上調</td>
<td>超配</td>
<td>395.00 美元</td>
<td>355.00 美元</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上調</td>
<td>超配</td>
<td>380.00 美元</td>
<td>340.00 美元</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上調</td>
<td>超配</td>
<td>340.00 美元</td>
<td>334.00 美元</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上調</td>
<td>買入</td>
<td>380.00 美元</td>
<td>350.00 美元</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 針對動態市場條件和公司表現，分析師更新他們的建議。無論是 ‘維持’、‘上調’ 還是 ‘下調’，都表明他們對 Cencora 近期發展的反應。這一見解提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 提供預測見解，分析師賦予定性值，從 ‘超配’ 到 ‘跑輸大盤’。這些評級傳達了對 Cencora 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 理解預測，分析師提供 Cencora 未來價值的估計。審視當前和之前的目標提供了分析師預期變化的見解。</li>
</ul>
<p>為了獲取 Cencora 市場表現的有價值見解，請將這些分析師評估與關鍵財務指標結合考慮。保持信息靈通，利用我們的評級表做出明智的決策。</p>
<p>隨時瞭解 Cencora 分析師評級。</p>
<h2>揭示 Cencora 背後的故事</h2>
<p>Cencora 是三家領先的國內製藥批發商之一。它向藥房（零售連鎖店、獨立藥房和郵購）、醫院網絡和醫療服務提供商採購和分銷品牌、仿製藥和特種藥品。它與 McKesson 和 Cardinal Health 共同佔據美國製藥批發行業 90% 以上的市場份額。Cencora 還為製藥和醫療設備製造商提供商業化服務，全球特種藥物物流（World Courier）以及動物健康產品分銷（MWI Animal Health）。Cencora 在 2021 年通過收購歐洲領先的藥品批發商 Alliance Healthcare 擴大了其國際業務。</p>
<h3>深入分析 Cencora 的財務狀況</h3>
<p><strong>市值分析：</strong> 該公司的市值高於行業平均水平，表明其相較於同行規模較大。這可能暗示着更高的投資者信心和市場認可度。</p>
<p><strong>積極的收入趨勢：</strong> 審視 Cencora 過去 3 個月的財務狀況顯示出積極的敍述。截止 2025 年 9 月 30 日，該公司實現了 <strong>5.92%</strong> 的顯著收入增長率，展現了頂線收益的顯著增加。與醫療保健行業的其他公司相比，該公司的增長率高於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Cencora 的淨利潤率超過行業標準，突顯了公司的卓越財務表現。其淨利潤率為 <strong>-0.41%</strong>，公司有效管理成本，實現了強勁的盈利能力。</p>
<p><strong>股本回報率（ROE）：</strong> Cencora 的 ROE 超越行業基準，達到 <strong>-19.48%</strong>。這表明了強大的財務管理和股東權益資本的有效利用。</p>
<p><strong>資產回報率（ROA）：</strong> Cencora 的 ROA 超越行業基準，達到 <strong>-0.45%</strong>。這表明了資產管理的高效性和強健的財務健康狀況。</p>
<p><strong>債務管理：</strong> Cencora 的債務與股本比率超過行業規範，達到 <strong>5.08</strong>。這表明公司承擔了相當數量的債務，可能面臨潛在的財務挑戰。</p>
<h2>分析師評級的重要性解析</h2>
<p>分析師是銀行和金融系統中的專家，通常為特定股票或特定行業報告。這些人研究公司財務報表，參加電話會議和會議，並與相關內部人士交談，以確定股票的分析師評級。通常，分析師每季度會對每隻股票進行評級。</p>
<p>除了他們的評估，一些分析師通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專業人士，分析師仍然是人類，只能根據他們的信念提供預測。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

制藥 ETF - VanEck Vectors

動態制藥業投資組合 ETF - Invesco

美國制藥 ETF - iShares

標普制藥指數 ETF - SPDR

<p>Cencora (NYSE:COR) 已被 11 位分析師評估，顯示出看漲和看跌情緒的混合。12 個月的平均目標價為 393.82 美元，較之前的目標上漲 11.98%。最近的分析師行動包括評級上調和下調，其中 Jefferies 和 JP Morgan 的調高尤為顯著。作為一家主要的製藥批發商，Cencora 顯示出 5.92% 的正收入增長和強勁的財務指標，儘管其負債與股本比率高達 5.08。分析師評級為市場預期和公司表現提供了洞察</p>

<p>Cencora (NYSE: COR) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>Cencora（紐約證券交易所代碼：COR）在過去三個月內被 11 位分析師分析，揭示了從看漲到看跌的多樣化觀點。</p>
</div><p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表概括了他們最近的評級，提供了過去 30 天情緒變化的快照，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $393.82, a high estimate of $440.00, and a low estimate of $340.00. This upward trend is apparent, with the current average reflecting a 11.98% increase from the previous average price target of $351.70.</p>
<div class="lb-trans"><p>分析師提供的 12 個月價格目標顯示出平均目標為 393.82 美元，最高預估為 440.00 美元，最低預估為 340.00 美元。這一上升趨勢顯而易見，目前的平均值較之前的 351.70 美元的平均價格目標增加了 11.98%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769119275_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769119275_0.png"/></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<div class="lb-trans"><h2>分析師評級探討：深入概述</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive Cencora. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過審視最近的分析師行動，我們可以瞭解金融專家如何看待 Cencora。以下摘要概述了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$440.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$400.00</td>
<td>-</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$417.00</td>
<td>$344.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$395.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$340.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>上調</td>
<td>買入</td>
<td>440.00 美元</td>
<td>330.00 美元</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>下調</td>
<td>中性</td>
<td>360.00 美元</td>
<td>380.00 美元</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>宣佈</td>
<td>超配</td>
<td>400.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>上調</td>
<td>超配</td>
<td>417.00 美元</td>
<td>344.00 美元</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>上調</td>
<td>超配</td>
<td>405.00 美元</td>
<td>354.00 美元</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>上調</td>
<td>買入</td>
<td>400.00 美元</td>
<td>350.00 美元</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上調</td>
<td>買入</td>
<td>415.00 美元</td>
<td>380.00 美元</td>
</tr>
<tr>
<td>David Rodgers</td>
<td>Baird</td>
<td>上調</td>
<td>超配</td>
<td>395.00 美元</td>
<td>355.00 美元</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上調</td>
<td>超配</td>
<td>380.00 美元</td>
<td>340.00 美元</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>上調</td>
<td>超配</td>
<td>340.00 美元</td>
<td>334.00 美元</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>上調</td>
<td>買入</td>
<td>380.00 美元</td>
<td>350.00 美元</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cencora. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cencora compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Cencora's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 針對動態市場條件和公司表現，分析師更新他們的建議。無論是 ‘維持’、‘上調’ 還是 ‘下調’，都表明他們對 Cencora 近期發展的反應。這一見解提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 提供預測見解，分析師賦予定性值，從 ‘超配’ 到 ‘跑輸大盤’。這些評級傳達了對 Cencora 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 理解預測，分析師提供 Cencora 未來價值的估計。審視當前和之前的目標提供了分析師預期變化的見解。</li>
</ul>
</div><p>For valuable insights into Cencora's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了獲取 Cencora 市場表現的有價值見解，請將這些分析師評估與關鍵財務指標結合考慮。保持信息靈通，利用我們的評級表做出明智的決策。</p>
</div><p>Stay up to date on Cencora analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Cencora 分析師評級。</p>
</div><h2>Unveiling the Story Behind Cencora</h2>
<div class="lb-trans"><h2>揭示 Cencora 背後的故事</h2>
</div><p>Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.</p>
<div class="lb-trans"><p>Cencora 是三家領先的國內製藥批發商之一。它向藥房（零售連鎖店、獨立藥房和郵購）、醫院網絡和醫療服務提供商採購和分銷品牌、仿製藥和特種藥品。它與 McKesson 和 Cardinal Health 共同佔據美國製藥批發行業 90% 以上的市場份額。Cencora 還為製藥和醫療設備製造商提供商業化服務，全球特種藥物物流（World Courier）以及動物健康產品分銷（MWI Animal Health）。Cencora 在 2021 年通過收購歐洲領先的藥品批發商 Alliance Healthcare 擴大了其國際業務。</p>
</div><h3>A Deep Dive into Cencora's Financials</h3>
<div class="lb-trans"><h3>深入分析 Cencora 的財務狀況</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 該公司的市值高於行業平均水平，表明其相較於同行規模較大。這可能暗示着更高的投資者信心和市場認可度。</p>
</div><p><strong>Positive Revenue Trend:</strong> Examining Cencora's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>5.92%</strong> as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<div class="lb-trans"><p><strong>積極的收入趨勢：</strong> 審視 Cencora 過去 3 個月的財務狀況顯示出積極的敍述。截止 2025 年 9 月 30 日，該公司實現了 <strong>5.92%</strong> 的顯著收入增長率，展現了頂線收益的顯著增加。與醫療保健行業的其他公司相比，該公司的增長率高於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Cencora's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.41%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Cencora 的淨利潤率超過行業標準，突顯了公司的卓越財務表現。其淨利潤率為 <strong>-0.41%</strong>，公司有效管理成本，實現了強勁的盈利能力。</p>
</div><p><strong>Return on Equity (ROE):</strong> Cencora's ROE excels beyond industry benchmarks, reaching <strong>-19.48%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Cencora 的 ROE 超越行業基準，達到 <strong>-19.48%</strong>。這表明了強大的財務管理和股東權益資本的有效利用。</p>
</div><p><strong>Return on Assets (ROA):</strong> Cencora's ROA excels beyond industry benchmarks, reaching <strong>-0.45%</strong>. This signifies efficient management of assets and strong financial health.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Cencora 的 ROA 超越行業基準，達到 <strong>-0.45%</strong>。這表明了資產管理的高效性和強健的財務健康狀況。</p>
</div><p><strong>Debt Management:</strong> Cencora's debt-to-equity ratio surpasses industry norms, standing at <strong>5.08</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Cencora 的債務與股本比率超過行業規範，達到 <strong>5.08</strong>。這表明公司承擔了相當數量的債務，可能面臨潛在的財務挑戰。</p>
</div><h2>The Significance of Analyst Ratings Explained</h2>
<div class="lb-trans"><h2>分析師評級的重要性解析</h2>
</div><p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.</p>
<div class="lb-trans"><p>分析師是銀行和金融系統中的專家，通常為特定股票或特定行業報告。這些人研究公司財務報表，參加電話會議和會議，並與相關內部人士交談，以確定股票的分析師評級。通常，分析師每季度會對每隻股票進行評級。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他們的評估，一些分析師通過提供關鍵指標的預測，如收益、收入和增長預期，來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專業人士，分析師仍然是人類，只能根據他們的信念提供預測。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

通過 11 位分析師的視角，瞭解 Cencora 的專家展望